Pharmacopeia Adds Executive Vice President, Corporate Development and Senior Vice President, Chemistry and Preclinical Chemical Development
PRINCETON, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the appointments of Eric J. Liebler as Executive Vice President, Corporate Development and S. David Kimball, Ph.D., as Senior Vice President, Chemistry and Preclinical Chemical Development.
In this new position, Mr. Liebler will employ his broad experience in strategy and corporate development to refine the Company's progress towards product commercialization, including the identification of opportunities that leverage Pharmacopeia's high-value assets.
Prior to joining Pharmacopeia, Mr. Liebler served most recently as Senior Vice President, Strategic Planning at Questcor Pharmaceuticals and held executive-level positions with Enzon Pharmaceuticals, Elan Corporation, Amarin Pharmaceuticals, and Athena Neurosciences. Mr. Liebler currently serves as Vice Chairman of the Board of Trustees of the American Academy of Neurology Foundation.
"Eric brings expertise in areas that are critical to Pharmacopeia's continued building of our business," said Les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "Together with David, these key additions to our management team are important to sustaining the significant momentum that we have generated."
Dr. Kimball joins the Pharmacopeia team with more than 25 years of
experience in drug discovery. As Pharmacopeia's Senior Vice President,
Chemistry and Preclinical Chemical Development, Dr. Kimball will be
responsible for
'/>"/>
| SOURCE Pharmacopeia Copyright©2007 PR Newswire. All rights reserved |